Posted by Michael Wonder on 18 Jun 2024
US FDA rare paediatric disease designation granted to RC220 bisantrene for the treatment of paediatric AML
18 June 2024 - Race Oncology is pleased to announce that the US FDA has extended rare paediatric disease designation to RC220 bisantrene for the treatment of childhood (paediatric) sub-types of acute myeloid leukaemia.
Rare paediatric disease designation was previously granted by the US FDA to RC110 bisantrene in 2018.
